Next Article in Journal
cml Biology for the Clinician in 2011: Six Impossible Things to Believe before Breakfast on the Way to Cure
Previous Article in Journal
Triple-Negative Breast Cancers: An Updated Review on Treatment Options
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Open AccessArticle

Canadian Expert Group Consensus Recommendations: KRAS Testing in Colorectal Cancer

1
Centre Hospitalier de l’Université de Montréal, 1560 Sherbrooke Street East, Montreal, QC H2L 4M1, Canada
2
BC Cancer Agency, Vancouver, BC, Canada
3
Mount Sinai Cancer Centre, Toronto, ON, Canada
4
Nova Scotia Cancer Centre, Halifax, NS, Canada
5
Princess Margaret Hospital, Toronto, ON, Canada
6
Cross Cancer Centre, Edmonton, AB, Canada
7
Hôpital Charles-Lemoyne, Greenfield Park, QC, Canada
8
CancerCare Manitoba, Winnipeg, MB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2011, 18(4), 180-184; https://doi.org/10.3747/co.v18i4.779
Received: 4 May 2011 / Revised: 3 June 2011 / Accepted: 2 July 2011 / Published: 1 August 2011
Monoclonal antibodies against the epidermal growth factor receptor (anti-egfr) when used in the treatment of metastatic colorectal cancer are associated with improved survival. Patients whose tumours harbor a KRAS mutation in codon 12 or 13 have been shown not to benefit from anti-egfr antibodies. The importance of KRAS mutation status in the management of patients with metastatic colorectal cancer has led to the elaboration of Canadian consensus recommendations on KRAS testing, with the aim of standardizing practice across Canada and reconciling testing access with the clinical demand for testing. The present guidelines were developed at a Canadian consensus meeting held in Montreal in April 2010. The best available evidence and expertise were used to develop recommendations for various aspects of KRAS testing, including indications and timing for testing, sample requirements, recommendations for reporting requirements, and acceptable turnaround times.
Keywords: KRAS mutations testing; BRAF mutations testing; metastatic colorectal cancer; guidelines; consensus recommendations; cetuximab; panitumumab; anti-egfr therapy KRAS mutations testing; BRAF mutations testing; metastatic colorectal cancer; guidelines; consensus recommendations; cetuximab; panitumumab; anti-egfr therapy
MDPI and ACS Style

Aubin, F.; Gill, S.; Burkes, R.; Colwell, B.; Kamel–Reid, S.; Koski, S.; Pollett, A.; Samson, B.; Tehfe, M.; Wong, R.; Young, S.; Soulières, D. Canadian Expert Group Consensus Recommendations: KRAS Testing in Colorectal Cancer. Curr. Oncol. 2011, 18, 180-184. https://doi.org/10.3747/co.v18i4.779

AMA Style

Aubin F, Gill S, Burkes R, Colwell B, Kamel–Reid S, Koski S, Pollett A, Samson B, Tehfe M, Wong R, Young S, Soulières D. Canadian Expert Group Consensus Recommendations: KRAS Testing in Colorectal Cancer. Current Oncology. 2011; 18(4):180-184. https://doi.org/10.3747/co.v18i4.779

Chicago/Turabian Style

Aubin, F.; Gill, S.; Burkes, R.; Colwell, B.; Kamel–Reid, S.; Koski, S.; Pollett, A.; Samson, B.; Tehfe, M.; Wong, R.; Young, S.; Soulières, D. 2011. "Canadian Expert Group Consensus Recommendations: KRAS Testing in Colorectal Cancer" Curr. Oncol. 18, no. 4: 180-184. https://doi.org/10.3747/co.v18i4.779

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop